The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
In a study for the drug VX-135, patients developed increased levels of liver enzymes. The FDA has put a partial clinical hold on the drug until they can fully study their toxicity concerns.
Continue reading »Once a day dosage of Simeprevir for patients has shown that it is safe to take and, thus far, has very little drug interactions. As such a complex disease, those with Hepatitis C need many medication and treatment options so that they may have a chance at recovery.
Continue reading »Researchers are attempting to create a version of bilirubin, a fluid made by our liver – and also found in unagi eels – because it may help treat liver disease.
Continue reading »A new test has been designed by Abbot Laboratories that can single out seven different varieties of Hepatitis C.
Continue reading »Before starting clinical evaluations, the FDA demands more safety data on Idenix Pharmaceuticals’ new drug.
Continue reading »Korean researchers have developed RNA aptamers, potential drug agents that appear to prevent the persistent problem of Hepatitis C antiviral drug resistance.
Continue reading »Comparing four different methods of treatment, an analytic model showed that an all-oral, interferon-free, treat-all regimen was the most cost-effective approach for treating chronic Hepatitis C genotype 1.
Continue reading »In a Phase III Hepatitis C trial of triple therapy with pegylated interferon and ribavirin, simeprevir proves itself by leading to sustained virologic response in nearly 80 percent of patients.
Continue reading »Due to positive results from three Phase III trials, the FDA has granted a priority review to simeprevir, a Hepatitis C protease inhibitor that is administered with interferon and ribavirin therapy.
Continue reading »Major improvements in Hepatitis C treatment response were seen when simeprevir was added to interferon-based therapy.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
